Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01352637 · ClinicalTrials.gov registry record · Phase 3
Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer
A Phase 3 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
NCT01352637: Completed Phase 3 study, sponsored by Weill Medical College of Cornell University.
NCT01352637 is a Phase 3 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 192 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01352637, a Phase 3 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
Study Summary
The purpose of this study is to test the differences between four active treatment conditions for combat-related Post Traumatic Stress Disorder (PTSD): virtual reality exposure therapy (VRE) or prolonged imaginal exposure therapy (PE), both with DCS or placebo, as well as to examine predictors for PTSD and response to treatment in active duty military personnel, veterans, and civilians who served in Iraq and Afghanistan.
Primary Outcome
Clinician Administered PTSD Scale (CAPS) for the DSM-IV \[34\]. The CAPS-IV is a structured clinical interview designed to assess the 17 DSM-IV PTSD symptoms. CAPS-IV provides categorical ratings of diagnostic status as well as a quantitative index of symptom severity. The CAPS total severity score is based on response to the 17 items that assess the frequency and intensity of current PTSD symptoms. Symptom severity is assessed separately for past month and past week time frames. CAPS-IV range
Interventions
- DRUG DCS (D-Cycloserine ) + Prolonged Imaginal Exposure
- DRUG DCS (D-Cycloserine ) + Virtual Reality Exposure
- DRUG Placebo + Prolonged Imaginal Exposure
- DRUG Placebo (sugar pill) + Virtual Reality Exposure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2011-05 |
| Est. Completion | 2018-09 |
| Phase | Phase 3 |
What the finished NCT01352637 record still lists
NCT01352637 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 4 interventions - of which DCS (D-Cycloserine ) + Prolonged Imaginal Exposure is the first listed.
NCT01352637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01352637 about?
NCT01352637 is a clinical study titled "Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer". The purpose of this study is to test the differences between four active treatment conditions for combat-related Post Traumatic Stress Disorder (PTSD): virtual reality exposure therapy (VRE) or prolonged imaginal exposure therapy (PE), both with DCS or placebo, as well as to examine predictors for P...
What is the current status of trial NCT01352637?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2011-05. Estimated completion is 2018-09.
What interventions are being tested in trial NCT01352637?
The interventions under investigation include: DCS (D-Cycloserine ) + Prolonged Imaginal Exposure (DRUG), DCS (D-Cycloserine ) + Virtual Reality Exposure (DRUG), Placebo + Prolonged Imaginal Exposure (DRUG), Placebo (sugar pill) + Virtual Reality Exposure (DRUG).
Who is sponsoring clinical trial NCT01352637?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01352637's enrollment target sits among peer trials
192 1398th of 2000 higher than 599 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia